Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that is indicated to treat Lambert-Eaton myasthenic syndrome.
Product Name : Firdapse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Catalyst Pharma Sub-Licensee Gets Approval For FIRDAPSE® in Japan
Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that received approval to treat Lambert-Eaton myasthenic syndrome in Japan.
Product Name : Firdapse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization.
Product Name : Firdapse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : DyDo Pharma will have joint rights to develop Firdapse® (amifampridine phosphate), and exclusive rights to commercialize the product, in Japan. Firdapse® is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that slows or inhibits ...
Product Name : Firdapse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Firdapse (amifampridine phosphate) is a broad spectrum potassium channel blocker. Amifampridine is the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Product Name : Firdapse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2021
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Catalyst Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable